Remicade

Reports of Neurological Side Effects

Remicade (Infliximab) is an immune-suppressing drug used to treat rheumatoid arthritis and Crohn's disease. It is manufactured by Centocor and distributed by Johnson & Johnson. Reports of adverse side effects have prompted the maker to issue warnings to healthcare providers citing reports of CNS (central nervous system) disorders and hematologic events.

The warning issued by Centocor states, "Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients taking Remicade.""Discontinuation of Remicade therapy should be considered in patients who develop significant hematologic abnormalities."

In October, 2001 Centocor issued a "black box warning" to healthcare professionals noting that, "tuberculosis and other serious opportunistic infections, including histoplasmosis, listeriosis, and pneumocystosis, have been reported in both the clinical research and post marketing surveillance settings."

Remicade Updates

FDA Investigating Remicade, Enbrel, Humira and Cimzia Link to Cancers
The U.S. Food and Drug Administration (FDA) on Wednesday issued an Early Communication release stating that it is investigating a possible association between tumor necrosis factor (TNF) blockers and the development of cancers in children and young adults. The TNF blockers were prescribed to treat Juvenile Idiopathic Arthritis (JIA), Crohn's disease or other diseases.

Remicade in the News

Remicade Legal Help

If you or a family member have used Remicade in the past and have suffered any side effects, you may be entitled to compensation. Please click the link below to send your complaint to a lawyer who will review your claim at no cost or obligation.

Last updated on Jun-8-08